BioWorld

Feb. 20, 2007

Ziopharm Adds $31M For Clinical Oncology Pipeline

Ziopharm Oncology Inc. pulled in gross proceeds of $30.9 million in a private placement to advance ongoing clinical development of three lead cancer programs, two of which are expected enter pivotal testing this year. (BioWorld Today) Read More

Inspire Pads Late-Stage Pipeline With License To InSite's AzaSite

In Irritable Bowel Syndrome Pain, A General Mechanism

FDA Says No Strings Attached To PDUFA At Public Meeting

Holiday Notice

GPC's Satraplatin NDA Done, Drug Could Launch This Year

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Viva in vivo! At EHA, in vivo CAR T data continues to impress

BioWorld

Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...